Amy L. Burroughs has bought stock on 3 days since Aug 2021

Amy L. Burroughs is the Chief Executive Officer and a member of the Board of Directors at Terns Pharmaceuticals, Inc. (NASDAQ: TERN), a clinical-stage biopharmaceutical company focused on oncology and obesity therapeutics.( She joined the company in February 2024, succeeding Senthil Sundaram following his passing, at a time when Terns had discontinued a phase 2 program for metabolic dysfunction-associated steatohepatitis but maintained a strong balance sheet and promising pipeline including TERN-601 and TERN-701.(

Burroughs brings over 25 years of biopharmaceutical leadership experience. Most recently, she served as CEO at Cleave Therapeutics, leading financings, licensing deals, and clinical development of CB-5339 for acute myeloid leukemia.( Previously, she was Executive in Residence at 5AM Ventures and Senior Advisor to Crinetics Pharmaceuticals during its IPO, with earlier roles in commercial strategy at Genentech, business development at high-growth therapeutics firms, talent governance at Egon Zehnder International, and brand management at Procter & Gamble.( She holds an M.B.A. from Harvard Business School (Baker Scholar) and a B.A. in computer science with a minor in economics from Dartmouth College, and serves on the board and audit committees at Tenaya Therapeutics.( On March 16, 2026, she sold 14,583 shares of TERN stock for approximately $681,000 while retaining significant holdings.(

Written by Perplexity from public sources.